Merck & Co

News

NewAmsterdam goes public to advance drug in abandoned class

NewAmsterdam Pharma has charted out a route to a Nasdaq listing by merging with black cheque company Frazier Lifesciences in a deal that will provide additional cash for its main drug candi

News

After cough drug setback, Merck partners Hyfe's tracking app

Merck & Co has signed a deal with digital health firm Hyfe that will see its cough-detecting smartphone app offered to patients in the US.

News

Bid to expand Keytruda use in head and neck cancer therapy f...

While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact – as Merck & Co has just observed in a study of Keytruda in

News

Disappointment as Lynparza fails colorectal cancer test

AstraZeneca and Merck's PARP inhibitor Lynparza has carved out blockbuster revenues across uses in breast, ovarian, prostate and pancreatic cancer, but colorectal cancer won’t be added to t

News

Merck buys into Orion prostate cancer therapy in $290m deal

Merck & Co has added another clinical-stage drug to its oncology pipeline via a licensing agreement with Finland's Orion for ODM-208, a prostate cancer candidate currently in phase 2 te

News